retinol binding protein 7Genealiases: CRABP4 · CRBP4 · CRBPIV
Q-omics provides the consensus-scored RBP7 profile across patient tissues and cancer cell-line models. RBP7 expression is associated with patient survival in 28 of 34 cancer types, with the highest sampling consensus in KIRC. Among the 18 cancer types available for tumor–normal comparison, RBP7 is differentially expressed in 15, with the highest sampling consensus in KICH. Additionally, RBP7 protein abundance shows 21,359 significant protein co-abundance associations, with the highest sampling consensus in GBM. Together, these results highlight KIRC, KICH, and GBM as cancer lineages where RBP7 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for RBP7 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes RBP7 survival associations across molecular data types. RBP7 RNA expression shows survival associations in the most cancer types (28), followed by mass-spec protein abundance (4). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible RBP7 RNA expression–survival associations across cancer types. High RBP7 expression shows unfavorable associations in COAD, BLCA and KIRP, but favorable associations in KIRC, UVM and MESO. The KIRC Kaplan–Meier curve shows clear separation, with the low-expression group declining faster, consistent with the favorable association (log-rank p < 0.001). Together, the overview and detailed table identify KIRC as the clearest survival context for RBP7 RNA expression.
This table summarizes RBP7 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 15, while mass-spec protein shows differences in 6. The strongest signals are observed in THCA for RNA and HNSC for protein.
This table ranks reproducible tumor–normal expression differences for RBP7. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. RBP7 shows lower tumor expression in KICH, THCA, HNSC, BLCA and KIRP and higher tumor expression in LIHC. The KICH box plot shows higher RBP7 RNA expression in normal versus tumor tissue (log2 FC = −2.183, t-test p < 0.001).
This table shows molecular features associated with RBP7 in patient tissues and cancer cell lines. In patient samples, RBP7 shows the broadest associations at the RNA and protein expression levels, with GBM recurring as the lineage with the largest associated feature set. In cancer cell lines, RBP7 RNA and mutation anchors are most strongly linked to RNA-expression features, especially in BLOOD_Lymphoma, while CRISPR and shRNA rows add functional-dependency signals in SOFT_TISSUE and CNS.
